CARE Ratings Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹5,209 Cr
- Book Value
- ₹311
- Stock P/E
- 30.4
- Dividend Yield
- 1.27%
- ROE
- 19.7%
- ROCE
- 26.3%
- PEG Ratio
- 2.20
- EV/EBITDA
- 20.2
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Technical snapshot
EOD ·CARE Ratings Ltd closed at ₹1,706.70 on 19 August 2026, down 1.1% on the day, 1.5% above its 50-day average, 7.1% below its 52-week high, with volume at 1.08× its 20-session average.
- RSI 14
- 50.9
- vs 50-day SMA
- +1.5%
- vs 200-day SMA
- +5.4%
- From 52-week high
- -7.1%
- Relative volume
- 1.08×
- 20-day return
- +1.9%
End-of-day prices from exchange-published files (NSE/BSE bhavcopy), updated after market close. Descriptive statistics, not investment advice.
CARE Ratings share price today
CARE Ratings (NSE: CARERATING) holds the #2 domestic position in one of finance’s best structures: the credit-rating oligopoly. Regulation manufactures the demand — bonds and bank loans above thresholds must carry ratings from accredited agencies — and accreditation walls keep the club at a handful of members. The economics follow the structure: 41.7% operating margins, 26.3% ROCE, net cash, and a 1.3% dividend along the way.
The macro story is the multiplier: India’s corporate-bond market remains small relative to GDP against every developed benchmark, and each step of bond-market deepening — infra financing, NBFC diversification, insurance/pension demand for paper — is rated revenue. At 30.4×, the tension is whether bond-market deepening turns into fee growth quickly enough to support a fair-not-cheap annuity valuation.
The oligopoly’s second seat
CRISIL carries the premium and the global parent; CARE is the domestic pure-play where a re-rating (of the rater) has room to run. Rating revenue is annuity-shaped — surveillance fees recur for every instrument’s life — and operating leverage is steep: an incremental rating costs analysts’ hours, not capital. The institutional ownership (no promoter) keeps governance clean and the register open.
Watch-items: bond-issuance volumes (the cycle variable), pricing discipline among the agencies, regulatory changes to rating mandates, and reputational risk — one blown rating cycle (IL&FS-style) can cost years of trust.
The numbers
Financial snapshot — 5 August 2026
| Metric | Value |
|---|---|
| Market cap | ₹5,209 Cr |
| P/E (TTM) | 30.4 |
| EV/EBITDA | 20.2 |
| Operating margin | 41.7% |
| ROE / ROCE | 19.7% / 26.3% |
| Debt to equity | 0.03 (net cash) |
| Sales CAGR (5y) | 13.8% |
| Profit CAGR (5y) | 13.8% |
| Promoter holding | 0% (institutionally owned) |
| EPS (TTM) | ₹56.83 |
CARE Ratings share price target 2026 to 2030
EPS base ₹56.83 (TTM). Bear: issuance cycles soften — 8% growth, multiple at 19×. Base: bond-market deepening compounds — 13% growth at 26×. Bull: debt-market reforms accelerate issuance — 17% growth at 33×.
From ₹1,729, the base case is ≈ +57% over four and a half years plus the 1.3% yield; the bear is −8%. Regulated oligopolies compress politely — the range below is where polite becomes profitable.
Reasons to own CARE Ratings (at the right price)
- Regulation manufactures the demand — ratings are compliance, not discretion.
- Surveillance fees recur for every rated instrument’s life: annuity revenue.
- 42% OPM with net cash — oligopoly economics without balance-sheet risk.
- India’s bond-market deepening is a decade-length structural trade.
- The #2 seat carries re-rating room the premium incumbent doesn’t.
The risks: issuance volumes are cyclical, price competition among agencies flares periodically, and the entire franchise rests on reputational capital one crisis can dent.
What to weigh at the current price
CARE’s oligopoly economics are attractive, but 30.4× is a spectator’s price only if bond-market growth and rating volumes keep compounding.
FAQ
What is the CARE Ratings share price target for 2030? The table above sets out bear, base and bull scenarios for each year through 2030. These are valuation sensitivities, not promised prices.
Why does regulation guarantee rating demand? SEBI and RBI rules require accredited ratings for bond issues and large bank exposures — the product is mandatory, and the accredited club is tiny.
How does CARE differ from CRISIL? CRISIL blends ratings with a global analytics business under S&P’s control at a premium multiple; CARE is the cheaper domestic pure-play on the same oligopoly structure.
When are CARE Ratings’ next results? Check the results calendar and confirm the announced date in the relevant exchange filing.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.